Sourin Banerji, MD
Cardiovascular Disease · Newark, DENPI 1346443140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,520 of the $3,984 with a category attached, or 63.3%. Abbott accounts for 78.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $1,150 and has fallen 96.5% since, to $40 in 2025.
Across 81 payments — averaging $49.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Impulse Dynamics (USA) Inc.$347
- Abiomed$121
- Novartis$103
- Akcea Therapeutics, Inc.$84
- Boston Scientific$48
- plus $164 from 7 others
Across 40 payments — averaging $3175.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$56K
- American Regent$47K
- Abbott$13K
- Astrazeneca UK Limited$12K
What the payments were for
- Consulting fees$95024%
- Travel & lodging$51413%
- Food & beverage$2,52063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $3,117 |
| Impulse Dynamics (USA) Inc. | 3 | $347 |
| Abiomed | 5 | $121 |
| Novartis | 5 | $103 |
| Akcea Therapeutics, Inc. | 1 | $84 |
| Boston Scientific | 3 | $48 |
| Sensible Medical Innovations Inc | 1 | $46 |
| Pfizer | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Amgen | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,984 in reported general payments places this provider in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 57 | $85,724 |
| JardianceEmpagliflozin | 71 | $65,722 |
| FarxigaDapagliflozin Propanediol | 49 | $48,553 |
| EliquisApixaban | 34 | $36,976 |
| Bumetanide | 57 | $4,927 |
| Metoprolol Succinate | 96 | $1,842 |
| Potassium Chloride | 53 | $1,313 |
| Spironolactone | 100 | $617 |
| Midodrine Hcl | 16 | $498 |
| Carvedilol | 72 | $472 |
| Rosuvastatin Calcium | 32 | $432 |
| Furosemide | 79 | $414 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 12 | $329 |
| Hydralazine Hcl | 25 | $308 |
| Amiodarone Hcl | 15 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $103 | $85,72457 claims |
| PfizerEliquis | $26 | $36,97634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.